Medtronic (MDT) Company Report

Medtronic expects FY27 organic revenue growth to exceed 5.5%, excluding the impact of the 53rd week, driven by accelerating CAS momentum and upcoming product rollouts (Ardian, InterStim, Hugo).
The company targets high single-digit EPS growth in FY27, using the extra selling week to offset dilution from recent M&A, diabetes spin-off and tariff carryover.
Completed the acquisition of Scientia to strengthen neurovascular access and intends to pursue mid-sized tuck-ins (~$1–3 billion) that enhance product ecosystems and commercial synergies.
Key franchise updates: CAS PFA growth at ~80% in Q3; renal denervation launch has driven website clicks from 50 K to 2.2 M and opened 200+ accounts; Sphere-360 and Hugo robotic systems set to broaden med-surg offerings.
Progressing the MiniMed separation with a successful IPO and planning a spin-off within six months to enable focused capital allocation and long-term EPS accretion (full impact over a 13-month share average).

6 days ago

Transcript

Medtronic outlines FY2027 outlook, M&A strategy, MiniMed spin-off, and product pipeline

MDT

Guidance Update

M&A

Product Launch

Expects FY2027 organic revenue growth above 5.5%, excluding the impact of a 53rd week, and is targeting high single-digit EPS growth, driven by accelerating CAS and new portfolio innovations.
Pursuing a “tuck-in” M&A strategy focused on medium-sized deals (~$1–3 billion) that enhance ecosystem synergies, exemplified by the recent acquisition of Scientia to complement neurovascular access capabilities.
Completed the IPO of MiniMed, the second largest medtech offering, and plans a full spin-off approximately six months post-IPO, which will be accretive over time through share count reduction.
CAS market reached $13 billion in Q3 with 20% growth; Sphere-9’s combined PFA/RF mapping drives current momentum, and Sphere-360 has received CE mark with a US launch expected in ~18 months.
Early launch of the Simplicity renal denervation system generated strong demand, with web engagement rising from 50,000 to 2.2 million clicks and over 200 accounts opened, supported by focused reimbursement assistance.

6 days ago

Transcript

Medtronic outlines 2027 growth targets and M&A strategy at Leerink conference

MDT

Guidance Update

M&A

Product Launch

Medtronic expects 2027 organic growth above 5.5% (ex-53rd week) and commits to high single-digit EPS growth, leveraging the extra selling week to offset M&A and diabetes separation dilution.
Pursuing small to mid-size tuck-in M&A, exemplified by the Scientia acquisition, with a target deal sweet spot of $1–3 billion to build product synergies and ecosystem offerings.
Highlighted key product growth drivers: accelerating CAS growth, upcoming Sphere-360 launch, expansion in renal denervation, and strategic rollouts of Altaviva, StealthStation AiBLE and Hugo robotics.
Completed the MiniMed IPO (second-largest medtech IPO) and plan the diabetes business split within six months, positioning Medtronic RemainCo and MiniMed for distinct capital allocation and accretive impact.

6 days ago

Transcript

Medtronic details MiniMed IPO, growth outlook and key franchises at Barclays Healthcare Conference

MDT

Guidance Update

Product Launch

Middle East exposure is limited, representing only 2–3% of revenue with logistics under control and petroleum-derived inputs under 1% of COGS.
Launched the 10% MiniMed IPO pre-conflict; planning a full spin-off by end-2026 via a shareholder conversion roughly six months post-IPO, which is expected to be EPS-accretive.
FY27 outlook calls for accelerated organic growth above FY26 levels (excluding the 53rd week), improved gross margins post-MiniMed deconsolidation, SG&A leverage, and high single-digit EPS growth, despite higher interest costs and tariff carryover.
Cardiac Ablation Systems (CAS) is the fastest-growing franchise; dual-energy Sphere-9 catheter plus mapping drives share gains, Sphere-360 has CE mark (U.S. trials underway) for launch in ~18 months, and mapper hires are scaling with demand.
Growth programs: Ardian renal denervation will begin to contribute in FY27 as reimbursement builds; Hugo robotic surgery secured FDA approval, with initial installations in urology and planned expansion into GYN, hernia and general surgery.

6 days ago

Transcript

Medtronic outlines growth outlook and MiniMed separation at Barclays Healthcare Conference

MDT

Guidance Update

Product Launch

New Projects/Investments

Strategic separation of MiniMed: Completed IPO of ~10% stake just before regional conflict; plans a secondary split (~90% of shares) about six months later to reduce Medtronic’s share count and drive EPS accretion.
Robust FY27 outlook: Organic growth accelerating (5.5% in Q2, 6% in Q4) with expected gross-margin expansion post-MiniMed deconsolidation, SG&A leverage, and high single-digit EPS growth excluding the 53rd week effect.
Macro resilience: Middle East exposure is 2–3% of revenue with limited logistics impact; petroleum-derived inputs are <1% of COGS, mitigating sustained oil-price risk.
Key growth franchises: Cardiac Ablation Systems gaining share via Sphere-9 (dual RF/PFA) and PulseSelect platforms; Ardian renal denervation and Hugo robotic surgery set to contribute to revenue beginning in FY27.

6 days ago

Transcript

Medtronic outlines strategic divestiture and growth strategy at Barclays conference

MDT

Guidance Update

M&A

Product Launch

Middle East exposure is 2–3% of Medtronic’s revenue; potential logistics disruptions and higher oil prices have minimal impact as petroleum derivatives account for <1% of COGS.
MiniMed IPO launched at 10% of equity (up to 11% with greenshoe); Medtronic will offer existing shareholders conversion rights on the remaining 90% roughly six months post-IPO, with MiniMed representing 7% of revenue and 3% of EBIT.
For FY 2027, management targets accelerated organic growth vs FY 2026, improved gross margins after the MiniMed split, SG&A leverage, partial R&D reinvestment, and high single-digit EPS growth despite tariff carryover (~$300 million) and higher refinancing costs.
The CAS franchise is the fastest-growing, with a 4 pt share gain in Q3 driven by the Sphere-9 dual-energy catheter; Sphere-360 has received CE mark and is entering U.S. clinical trials for a launch in ~18 months.
Emerging businesses Ardian (hypertension therapy) and Hugo (surgical robotic system) will begin to impact results in FY 2027, as reimbursement pathways mature for Ardian and Hugo secured FDA approval with initial installations completed.

6 days ago

Transcript

Medtronic to acquire Scientia Vascular

MDT

M&A

Medtronic entered a definitive agreement to acquire private neurovascular specialist Scientia Vascular for $550 million, plus potential earn-outs and milestone payments.
Scientia’s guidewires and catheters will integrate with Medtronic’s neurovascular suite to enhance access and procedural efficiency in stroke care.
The deal is expected to close in H1 FY27, subject to regulatory approvals, and to be minimally dilutive to adjusted EPS in FY27 and accretive thereafter.
This acquisition completes Medtronic’s neurovascular portfolio for hemorrhagic and acute ischemic stroke, positioning it to drive better patient outcomes globally.

7 days ago

Press Release

Medtronic announces MiniMed IPO listing on Nasdaq

MDT

Delisting/Listing Issues

MiniMed Group, Inc. (Nasdaq: MMED) began trading today on the Nasdaq Global Select Market under the ticker MMED.
The IPO was oversubscribed and represents the second largest IPO in Medtech history.
The spin-off positions MiniMed as a standalone company to operate with greater agility and supports Medtronic’s strategy to focus on long-term value creation.
Geoff Martha, Medtronic’s CEO, highlighted the achievement despite challenging market conditions and congratulated the MiniMed leadership team.

Mar 6, 2026, 2:00 PM

Press Release

Medtronic subsidiary MiniMed prices IPO

MDT

Delisting/Listing Issues

MiniMed Group priced an IPO of 28 million shares at $20.00 per share, set to begin trading on Nasdaq under the ticker MMED on March 6, 2026.
Underwriters received a 30-day option to purchase up to 4.2 million additional shares, and Medtronic is expected to hold 90.03% of MiniMed (or 88.70% if the over-allotment option is fully exercised) post-offering.
The offering is expected to close on March 9, 2026, with net proceeds earmarked for general corporate purposes, repayment of intercompany debt, and additional consideration to Medtronic.

Mar 6, 2026, 12:35 AM

Press Release

MiniMed prices IPO at $20 per share

MDT

Delisting/Listing Issues

MiniMed priced its IPO of 28,000,000 shares at $20.00 each, kicking off trading on Nasdaq Global Select Market under “MMED” on March 6, 2026, with closing expected March 9, 2026.
Underwriters have a 30-day option for up to 4,200,000 additional shares, and Medtronic is expected to retain ~90.03% ownership (or 88.70% if the over-allotment is fully exercised) post-offering.
Net proceeds will support general corporate purposes, repay intercompany debt, and serve as consideration for assets transferred from Medtronic.